vTv Therapeutics Inc is a biopharmaceutical company that strives to improve the lives of patients through innovative therapies. Their corporate philosophy revolves around integrity, collaboration, and a commitment to patients. The company values scientific excellence and aims to develop targeted treatments for diseases with unmet medical needs. vTv Therapeutics Inc focuses on discovering and advancing potential therapies that address various therapeutic areas such as diabetes, Alzheimer's disease, and inflammatory disorders. By embracing cutting-edge research and leveraging strategic partnerships, vTv Therapeutics Inc aims to deliver effective and transformative solutions to patients worldwide.

vTv Therapeutics Inc is primarily present in the United States and focuses on the development and commercialization of innovative therapies for various diseases. With its headquarters located in High Point, North Carolina, vTv Therapeutics Inc operates and serves patients throughout the entire region of the United States.

vTv Therapeutics Inc has achieved several significant milestones. In 2017, the company successfully completed a Phase 3 clinical trial for their lead investigational drug, azeliragon, in Alzheimer's disease patients. Additionally, they have made advancements in their programs for type 1 diabetes, where their oral drug, TTP399, demonstrated promising results in Phase 2 studies. vTv Therapeutics Inc has also partnered with several renowned organizations for collaborative research and development, further enhancing their capabilities and expanding their pipeline. These achievements highlight vTv Therapeutics Inc's commitment to developing innovative treatments in the field of healthcare.

vTv Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for chronic diseases. Founded in 2015, vTv Therapeutics has a strong emphasis on research and development in the areas of neurology and diabetes. With a diverse pipeline of potential therapies, the company is committed to improving patient outcomes and addressing unmet medical needs. vTv Therapeutics is constantly exploring new therapeutic approaches and collaborations to advance the field of medicine. Through its dedication to scientific excellence and patient-centric focus, vTv Therapeutics Inc has established itself as a leading player in the biopharmaceutical industry.

The main competitors of vTv Therapeutics Inc in the market include pharmaceutical companies such as Eli Lilly and Company, Novo Nordisk A/S, and Sanofi SA. These companies are also engaged in the development and commercialization of innovative therapies and drugs to address various medical conditions.

vTv Therapeutics Inc is primarily active in the biotechnology industry.

The business model of vTv Therapeutics Inc focuses on the development and commercialization of innovative pharmaceutical products for the treatment of various diseases. The company applies its proprietary drug discovery platform to identify and research potential drug candidates that target specific cellular pathways involved in disease processes. Through strategic partnerships and collaborations, vTv Therapeutics aims to advance its pipeline of therapeutics and bring novel treatments to market. By leveraging their expertise in drug development, the company aims to address unmet medical needs and improve patients' lives.

vTv Therapeutics의 P/E 비율은 -28.87입니다.

vTv Therapeutics의 P/S 비율은 0입니다.

vTv Therapeutics에 대한 AlleAktien 품질 점수는 4/10입니다.

vTv Therapeutics에 대한 현재 매출은 계산할 수 없습니다.

예상되는 vTv Therapeutics 이익은 -1.01 백만 USD입니다.

vTv Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of diseases associated with the aging process. The company was founded in 2015 and is headquartered in High Point, North Carolina. Its business model is based on researching and developing innovative drugs and therapies to meet the needs of older patients and improve their quality of life. The company's main product is Azeliragon, a drug for the treatment of Alzheimer's disease currently in late-stage clinical development. In addition to Azeliragon, vTv Therapeutics Inc is also working on the development of TTP399, an oral drug for the treatment of type 1 diabetes, and HPP737, a broad-spectrum histone deacetylase inhibitor that may be used in the treatment of cancer and other inflammatory diseases. The company collaborates with academic institutions, biopharmaceutical companies, other organizations, and regulatory authorities to promote its research and development efforts and improve the effectiveness and safety of its products. Overall, the company is focused on developing innovative therapies for age-related diseases and improving the lives of patients worldwide.

vTv Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

vTv Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

vTv Therapeutics의 ISIN은 US9183851057입니다.

vTv Therapeutics의 WKN은 A14XHJ입니다.

vTv Therapeutics의 티커는 VTVT입니다.

지난 12개월 동안 vTv Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 vTv Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

vTv Therapeutics의 현재 배당 수익률은 입니다.

vTv Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

vTv Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

vTv Therapeutics은 '건강' 섹터에 속합니다.

vTv Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 vTv Therapeutics는 0 USD를 배당금으로 지급했습니다.

vTv Therapeutics의 배당금은 USD에 지급됩니다.